13 research outputs found
Comparison of responders and non-responders to MQX-503, a novel investigational topical nitroglycerin formulation, in treatment of scieroderma-related and non-scleroderma-related Raynaud's phenomenon
No full textSecular humanitarians and the postsecular: reflections on Habermas and the Typhoon Haiyan disaster response
No full textAre heat and cold resistance of arctic species affected by successive extreme temperature events?
No full text
Are heat and cold resistance of arctic species affected by successive extreme temperature events?
No full text
Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease
No full textRationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear
